Chemotherapy in the Management of Advanced Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients: Theoretical and Practical Considerations

Dermatologic Surgery

Volumn 30, Issue 4 II, 2004, Pages 679-686

  Martinez, Juan Carlos ^a   Otley, Clark C ^b   Okuno, Scott H ^b   Foote, Robert L ^b   Kasperbauer, Jan L ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN DERIVATIVE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK SURGERY; HUMAN; METASTASIS; METASTASIS INHIBITION; ONCOLOGY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN CARCINOMA; SKIN SURGERY; SQUAMOUS CELL CARCINOMA; THEORETICAL STUDY;

EID: 1942540049     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30156.x     Document Type: Review

References (86)

1. Glover M, Niranjan N, Kwan J, Leigh I. Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994;47:86-9.
2. Sheil A. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 1992;24:1275-9.
3. Penn I. Post-transplant malignancy. the role of immunosuppression. Drug Saf 2000;23:101-13.
4. Ong C, Keogh A, Kossard S, Macdonald P, Spratt P. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999;40:27-34.
5. Penn I, First M. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation 1999;68:1717-21.
6. Veness M, Quinn D, Ong C, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999;85:1758-64.
7. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995;27:1767-8.
8. Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Transplant Proc 1998;30:1124-6.
9. Pollard J, Hanasono M, Mikulec A, Le Q, Terris D. Head and neck cancer in cardiothoracic transplant recipients. Laryngoscope 2000;110:1257-61.
10. Berg D, Otley C. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002;47:1-17.
11. Martinez J, Otley C, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003;139:301-6.
12. Jacobs C. Head and neck cancer in 1994: a change in the standard of care. J Natl Cancer Inst 1994;86:250-2.
13. Aisner J, Jacobs M, Sinabaldi V, Gray W, Eisenberger M. Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. Semin Oncol 1994;21:35-44.
14. Vokes E, Weichselbaum R, Lippman S, Hong W. Head and neck cancer. N Engl J Med 1993;328:184-94.
15. Marcial V, Pajak T, Kramer S, et al. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer. Semin Oncol 1988;15:39-60.
16. Lamont E, Vokes E. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2001;2:261-9.
17. Brown AJ, Blom J, Butler W, et al. Combination chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck. Cancer 1980;45:2830-5.
18. Randolph V, Vallejo A, Spiro R, et al. Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer 1978;41:460-7.
19. Schuller D, Metch B, Stein D, Mattox D, McCracken J. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-11.
20. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-72.
21. Jaulerry C, Rodriguez J, Brunin F, et al. Induction chemotherapy in advanced head and neck tumors: results of two randomized trials. Int J Radiat Oncol Biol Phys 1992;23:483-9.
22. Lefebvre J, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer. preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-9.
23. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of the Head and Neck Contracts Program. Cancer 1987;60:301-11.
24. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-90.
25. Browman G. Evidence-based recommendations against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer. Cancer Invest 1994;12:662-70.
26. Stell P, Rawson N. Adjuvant chemotherapy in head and neck cancer. Br J Cancer 1990;61:779-87.
27. Munro A. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83-91.
28. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838-47.
29. Pignon J, Bourhis J, Domenge C, Designe L. Chemotherapy added, to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet Oncol 2000;355:949-55.
30. Forastiere A. Randomized trials of induction chemotherapy: a critical review. Hematol Oncol Clin North Am 1991;5:725-36.
31. Dimery I, Hong W. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
32. Adelstein D, Tan E, Lavertu P. Treatment of head and neck cancer: the role of chemotherapy. Crit Rev Oncol Hematol 1996;24:97-116.
33. Urba S, Wolf G, Bradford C, et al. Neoadjuvant therapy for organ preservation in head and neck cancer. Laryngoscope 2000;110:2074-80.
34. Hainsworth J, Meluch A, McClurkan S, et al. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 2002;8:311-21.
35. Kukla L, Mantravadi R, Applebaum E, McGuire W. Preirradiation chemotherapy for advanced head and neck carcinomas. Arch Otolaryngol 1984;110:78-81.
36. Vokes E, Weichselbaum R, Mick R, et al. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 1992;84:877-82.
37. Clark J, Busse P, Norris CJ, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997;15:3100-10.
38. Vokes E, Haraf D, Kies M. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol 2000;27:34-8.
39. Milas L, Mason K, Liao Z, Ang K. Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003;25:152-67.
40. Wendt T, Grabenbauer G, Rodel C, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.
41. Haffty B. Concurrent chemoradiation in the treatment of head and neck cancer. Hematol Oncol Clin North Am 1999;13:719-42.
42. Brizel D. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol 1998;8:237-46.
43. Benasso M, Merlano M, Sanguineti G, et al. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study. Am J Clin Oncol 2001;24:618-22.
44. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6.
45. Brizel D, Albers M, Fisher S, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
46. Regine W, Valentino J, John W, et al. High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study. Head Neck 2000;22:543-9.
47. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
48. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997;43:29-37.
49. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003;55:93-8.
50. Lundahl R, Foote R, Bonner J, et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1998;40:529-34.
51. Olsen K, Caruso M, Foote R, et al. Primary head and neck cancer: histopathologic predictors of recurrence after neck dissection in patients with lymph node involvement. Arch Otolaryngol Head Neck Surg 1994;120:1370-4.
52. Peters L, Goepfert H, Ang K, et al. Evaluation of the dose for post-operative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993;26:3-11.
53. Kramer S, Gelber R, Snow J, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 1987;10:19-30.
54. Ang K, Trotti A, Brown B, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-8.
55. Laramore G, Scott C, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1s992;23:705-13.
56. Bachaud J, Cohen-Jonathan E, Alzieu C, et al. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004.
57. Johnson J, Wagner R, Myers E. A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. Cancer 1996;77:181-5.
58. Hathaway B, Johnson J, Piccirillo J, et al. Chemoradiation for metastatic SCCA. role of comorbidity. Laryngoscope 2001;111:1893-5.
59. Gupta N, Pointon R, Wilkinson P. A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol 1987;38:575-81.
60. Fu K, Phillips T, Silverberg I, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410-8.
61. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program. J Clin Oncol 1990;8:838-47.
62. de Braud F, Heilbrun L, Ahmed K, et al. Metastatic squamous cell carcinoma of an unknown primary localized to the neck: advantages of an aggressive treatment. Cancer 1989;64:510-5.
63. Forastiere A. Head and neck cancer: overview of recent developments and future directions. Semin Oncol 2000;27:1-4.
64. Bernier J, Domenge C, Eschewage F, Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC Phase III Trial 22931. Int J Radiat Oncol Biol Phys 2001;51 (Suppl):1.
65. Cooper J, Pajak TF, Forastiere AA, Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck. intial report of RTOG 9501/intergroup phase III trial [abstract 903]. Proc ASCO 2002;21:226a.
66. Shin D, Donato N, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13.
67. Kowalski L, Carvalho A. Natural history of untreated head and neck cancer. Eur J Cancer 2000;36:1032-7.
68. Kim E, Kies M, Herbst R. Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002;14:334-42.
69. Morton R, Rugman F, Dorman E, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985;15:283-9.
70. Khattab J, Urba S. Chemotherapy in head and neck cancer: overview of newer agents. Hematol Oncol Clin North Am 1999;13:753-68.
71. Glisson B, Murphy B, Frenette G, Khuri F, Forastiere A. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20:1593-9.
72. Forastiere A, Metch B, Schuller D, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
73. Clavel M, Cognetti F, Dodion P, et al. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer 1987;60:1173-7.
74. Baur M, Kienzer H, Schweiger J, et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 2002;94:2953-8.
75. Clavel M, Vermorken J, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521-6.
76. Khuri F, Shin D, Glisson B, Lippman S, Hong W. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol 2000;27:25-33.
77. Shin D, Glisson B, Khuri F, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002;20:364-70.
78. Guthrie TJ, Porubsky E, Luxenberg M, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990;8:342-6.
79. Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 1991;67:2030-2.
80. Sharma S, Sharma A, Singhal K. Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients. Zhongguo Yao Li Xue Bao 1990;11:288.
81. Sadek H, Azli N, Wendling J, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990;66:1692-6.
82. Salasche S, Bernstein G, Senkarik M. Lymphatics of the Head and Neck: Surgical Anatomy of the Skin. E. Norwalk (CT): Appleton & Lange, 1988:p. 141-9.
83. Lazarus H, Herzig R, Bornstein R, Laipply T. Metastatic squamous cell carcinoma of the skin. J Natl Med Assoc 1980;72:1196-9.
84. Dinehart S, Pollack S. Metastases from squamous cell carcinoma of the skin and lip: an analysis of twenty-seven cases. J Am Acad Dermatol 1989;21:241-8.
85. Epstein E, Epstein N, Bragg K, Linden Metastases from squamous cell carcinomas of the skin. Arch Dermatol 1968;97:245-51.
86. Swetter S, Smoller B, Bauer E. Cutaneous cancer and malignant melanoma. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, eds. Clinical Oncology. New York: Churchill Livingstone, 1995:p. 1023-45.